Condition
Donor Lymphocyte Infusion
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 2 (3)
Trial Status
Unknown2
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06643221Early Phase 1Recruiting
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
NCT03297528Phase 2UnknownPrimary
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
NCT02673008Phase 2Completed
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
NCT03771222Phase 2UnknownPrimary
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Showing all 4 trials